Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes | Zendy

Alison Offer | Zendy; Matthew Arnold | Zendy; Robert Clarke | Zendy; Derrick Bennett | Zendy; Louise Bowman | Zendy; Richard Bulbulia | Zendy; Richard Haynes | Zendy; Jing Li | Zendy; Jemma C. Hopewell | Zendy; Martin Landray | Zendy; Jane Armitage | Zendy; Rory Collins | Zendy; Sarah Parish | Zendy

Open Access

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes

Author(s) -

Alison Offer,

Matthew Arnold,

Robert Clarke,

Derrick Bennett,

Louise Bowman,

Richard Bulbulia,

Richard Haynes,

Jing Li,

Jemma C. Hopewell,

Martin Landray,

Jane Armitage,

Rory Collins,

Sarah Parish

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.0223

Subject(s) - medicine , type 2 diabetes , randomized controlled trial , diabetes mellitus , cognitive decline , dementia , incidence (geometry) , physical therapy , disease , cardiology , endocrinology , physics , optics

Key Points Question Do null results on cognitive function in cardiovascular trials exclude worthwhile benefit? Findings In this secondary analysis of 3 randomized clinical trials including 45 029 participants undergoing cognitive assessment, the prevention of nonfatal cardiovascular events in 4.5% of survivors in the Heart Protection Study, by randomization to statin, yielded an estimated cognitive function difference equivalent to avoiding 0.15 years of aging. By contrast, the trial was powered to detect a difference in cognitive aging of at least 1 year. Meaning Nonsignificant findings, even from large trials, should not be taken as good evidence of a lack of worthwhile benefit on cognitive function of prolonged use of cardioprotective therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research